Loading...
Loading...
Found 105 Skills
Guide pharmacogenomics (PGx) research -- drug-gene interaction lookup, CPIC guideline retrieval, variant-drug annotation, allele function status, FDA biomarker labeling, and clinical dosing recommendations. Covers the full CPIC-to-PharmGKB-to-clinical-recommendation workflow. Use when users ask about pharmacogenomics, drug-gene interactions, CPIC guidelines, genotype-guided dosing, PGx biomarkers, CYP enzyme phenotypes, or star allele interpretation.
Drug mechanism of action investigation -- systematic strategy to trace a drug from its primary target through pathways to clinical outcomes, identify off-target effects, and combine regulatory labels with literature evidence for a complete mechanism picture.
Comprehensive drug safety review integrating FDA labels, FAERS adverse event reports, disproportionality analysis, pharmacogenomics, clinical trials, and literature. Use for regulatory assessments, post-market surveillance, drug safety reviews, adverse event investigation, and pharmacovigilance.
Inorganic chemistry, physical chemistry, and materials science — crystal structures, coordination chemistry, bonding theory (covalency, orbital mixing), symmetry/point groups, thermodynamics, kinetics, spectroscopy interpretation, noble gas compounds, lanthanide/actinide chemistry. Use for questions about crystal systems, unit cells, density calculations, metal complexes, solid-state chemistry, or physical chemistry calculations.
Comprehensive structural variant (SV) analysis skill for clinical genomics. Classifies SVs (deletions, duplications, inversions, translocations), assesses pathogenicity using ACMG-adapted criteria, evaluates gene disruption and dosage sensitivity, and provides clinical interpretation with evidence grading. Use when analyzing CNVs, large deletions/duplications, chromosomal rearrangements, or any structural variants requiring clinical interpretation.
AI-driven patient-to-trial matching for precision medicine and oncology. Given a patient profile (disease, molecular alterations, stage, prior treatments), discovers and ranks clinical trials from ClinicalTrials.gov using multi-dimensional matching across molecular eligibility, clinical criteria, drug-biomarker alignment, evidence strength, and geographic feasibility. Produces a quantitative Trial Match Score (0-100) per trial with tiered recommendations and a comprehensive markdown report. Use when oncologists, molecular tumor boards, or patients ask about clinical trial options for specific cancer types, biomarker profiles, or post-progression scenarios.
Comprehensive immune repertoire analysis for T-cell and B-cell receptor sequencing data. Analyze TCR/BCR repertoires to assess clonality, diversity, V(D)J gene usage, CDR3 characteristics, convergence, and predict epitope specificity. Integrate with single-cell data for clonotype-phenotype associations. Use for adaptive immune response profiling, cancer immunotherapy research, vaccine response assessment, autoimmune disease studies, or repertoire diversity analysis in immunology research.
Comprehensive patient stratification for precision medicine by integrating genomic, clinical, and therapeutic data. Given a disease/condition, genomic data (germline variants, somatic mutations, expression), and optional clinical parameters, performs multi-phase analysis across 9 phases covering disease disambiguation, genetic risk assessment, disease-specific molecular stratification, pharmacogenomic profiling, comorbidity/DDI risk, pathway analysis, clinical evidence and guideline mapping, clinical trial matching, and integrated outcome prediction. Generates a quantitative Precision Medicine Risk Score (0-100) with risk tier assignment (Low/Intermediate/High/Very High), treatment algorithm (1st/2nd/3rd line), pharmacogenomic guidance, clinical trial matches, and monitoring plan. Use when clinicians ask about patient risk stratification, treatment selection, prognosis prediction, or personalized therapeutic strategy across cancer, metabolic, cardiovascular, neurological, or rare diseases.
Compare GWAS studies, perform meta-analyses, and assess replication across cohorts. Integrates NHGRI-EBI GWAS Catalog and Open Targets Genetics to compare study designs, effect sizes, ancestry diversity, and heterogeneity statistics. Use when comparing GWAS studies for a trait, performing meta-analysis of genetic loci, assessing replication across cohorts, or exploring the genetic architecture of complex diseases.